Elevated serum IL-10 levels in diffuse large B-cell lymphoma: A mechanism of aberrant JAK2 activation

Blood

Volumn 119, Issue 12, 2012, Pages 2844-2853

  Gupta, Mamta ^a   Han, Jing Jing ^a   Stenson, Mary ^a   Maurer, Matthew ^a   Wellik, Linda ^a   Hu, Guangzhen ^a   Ziesmer, Steve ^a   Dogan, Ahmet ^a   Witzig, Thomas E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR; I KAPPA B ALPHA; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 6; JANUS KINASE 2; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NEUTRALIZING ANTIBODY; PROTEIN BCL 2; STAT PROTEIN; STAT3 PROTEIN;

ADULT; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BLOOD LEVEL; CANCER PATIENT; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; EVENT FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNATIONAL PROGNOSTIC INDEX SCORE; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; SCORING SYSTEM; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84858848565     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-388538     Document Type: Article

References (48)

1. Levy DE, Inghirami G. STAT3: a multifaceted oncogene. Proc Natl Acad Sci U S A. 2006;103(27): 10151-10152. (Pubitemid 44051135)
2. Yu LF, Zhu YB, Qiao MM, Zhong J, Tu SP, Wu YL. Constitutive activation and clinical significance of Stat3 in human gastric cancer tissues and cell lines [Article in Chinese]. Zhonghua Yi Xue Za Zhi. 2004;84(24):2064-2069.
3. Berishaj M, Gao SP, Ahmed S, et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/ glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res. 2007;9(3):R32.
4. Gao H, Ward PA. STAT3 and suppressor of cytokine signaling 3: potential targets in lung inflammatory responses. Expert Opin Ther Targets. 2007;11(7):869-880. (Pubitemid 47061314)
5. Gao B, Shen X, Kunos G, et al. Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett. 2001; 488(3):179-184. (Pubitemid 32103593)
6. Lam LT, Wright G, Davis RE, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- {kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111(7):3701-3713.
7. Catlett-Falcone R, Dalton WS, Jove R. STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Curr Opin Oncol. 1999;11(6):490-496. (Pubitemid 29515894)
8. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15(2):103-113.
9. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005;41(16):2502-2512. (Pubitemid 41540626)
10. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273-287.
11. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651-662. (Pubitemid 34987786)
12. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7): 789-796.
13. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
14. Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011;118(15): 4053-4061.
15. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1):275-282. (Pubitemid 38029949)
16. Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood. 2009;114(14):2926-2935.
17. Gupta M, Dillon SR, Ziesmer SC, et al. A proliferation- inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinaseregulated mammalian target of rapamycin activation. Blood. 2009;113(21):5206-5216.
18. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765. (Pubitemid 32368050)
19. Barré B, Vigneron A, Perkins N, Roninson IB, Gamelin E, Coqueret O. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med. 2007;13(1):4-11. (Pubitemid 46027724)
20. Zushi S, Shinomura Y, Kiyohara T, et al. STAT3 mediates the survival signal in oncogenic rastransfected intestinal epithelial cells. Int J Cancer. 1998;78(3):326-330. (Pubitemid 28445370)
21. Lassmann S, Schuster I, Walch A, et al. STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation. J Clin Pathol. 2007; 60(2):173-179.
22. Burke WM, Jin X, Lin HJ, et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene. 2001;20(55):7925-7934. (Pubitemid 34002969)
23. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene. 2002;21(55):8404-8413. (Pubitemid 36054883)
24. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene. 2002;21(50):7611-7618. (Pubitemid 35398808)
25. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2003;101(4):1535-1542. (Pubitemid 36182531)
26. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol. 2004;22(9):1682-1688. (Pubitemid 41079807)
27. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
28. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24(19):3121-3127. (Pubitemid 46638950)
29. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100(17):9991-9996. (Pubitemid 37087056)
30. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B cell lymphoma. Blood. 2009;113(24):6069- 6076.
31. Valentino L, Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol. 2006;71(6): 713-721. (Pubitemid 43208827)
32. Ferrajoli A, Faderl S, Ravandi F, Estrov Z. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets. 2006;6(8):671-679. (Pubitemid 44875961)
33. Verstovsek S. Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosomenegative myeloproliferative neoplasms. J Clin Oncol. 2011;29(7):781-783.
34. Melzner I, Weniger MA, Menz CK, Moller P. Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia. 2006;20(1): 157-158.
35. Steensma DP, McClure RF, Karp JE, et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia. 2006;20(6):971-978. (Pubitemid 43797287)
36. Li N, Grivennikov SI, Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell. 2011; 19(4):429-431.
37. Nacinović-Duletić A, Stifter S, Dvornik S, Skunca Z, Jonjic N. Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma. Int J Lab Hematol. 2008;30(3):230-239. (Pubitemid 351695395)
38. Lech-Maranda E, Baseggio L, Bienvenu J, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood. 2004;103(9):3529-3534. (Pubitemid 38525688)
39. Blay JY, Burdin N, Rousset F, et al. Serum interleukin- 10 in non-Hodgkin's lymphoma: a prognostic factor. Blood. 1993;82(7):2169-2174. (Pubitemid 23294002)
40. Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001;97(1):256-263. (Pubitemid 32061268)
41. Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A. 1992;89(5):1890-1893.
42. MacNeil IA, Suda T, Moore KW, Mosmann TR, Zlotnik A. IL-10, a novel growth cofactor for mature and immature T cells. J Immunol. 1990; 145(12):4167-4173.
43. Villagra A, Cheng F, Wang HW, et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol. 2009;10(1):92-100.
44. Finbloom DS, Winestock KD. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol. 1995;155(3):1079-1090.
45. Baker SJ, Rane SG, Reddy EP. Hematopoietic cytokine receptor signaling. Oncogene. 2007; 26(47):6724-6737. (Pubitemid 47585098)
46. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer. Res. 2003;9(1):316-326. (Pubitemid 36109748)
47. Slack GW, Gascoyne RD. MYC and aggressive B-cell lymphomas. Adv Anat Pathol. 2011;18(3): 219-228.
48. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in downregulation of bcl-2 and sensitization of B-cell non- Hodgkin's lymphoma to apoptosis. Clin Cancer Res. 2001;7(3):709-723. (Pubitemid 32707998)